



June 2, 2016

**GNI Group Increases Equity Investment in
Beijing Continent Pharmaceuticals Co., Ltd.**

GNI Group is pleased to announce the acquisition of an additional two percent (2%) of Beijing Continent Pharmaceutical Co., Ltd. (Beijing Continent) equity shares from Beijing Kangdini Factory today. This transaction, disclosed on January 27, 2016, with one of the original shareholders of Beijing Continent increases GNI Group's equity ownership to 53% of this key subsidiary of our company. Through this investment, GNI Group further consolidates its control and increase its share of Beijing Continent's future profits.